Search company, investor...

Cardea Bio

cardeabio.com

Founded Year

2013

Stage

Grant | Alive

Total Raised

$22.9M

Last Raised

$1.1M | 9 mos ago

About Cardea Bio

Cardea Bio is a mass producer of biocompatible semiconductors, also called the BPU™ (Biosignal Processing Unit). The BPU is a semiconductor capable of translating real-time streams of multiomics signals into digital information. Through the BPU™ platform, Cardea's long-term vision is to democratize access to the biosignals and insights behind the most advanced technology on the planet: nature and biology. Cardea Bio was founded in 2013 and is based in San Diego, California.

Headquarters Location

8969 Kenamar Dr., Suite 104

San Diego, California, 92121,

United States

619-762-1142

Cardea Bio's Product Videos

Compete with Cardea Bio?

Ensure that your company and products are accurately represented on our platform.

Cardea Bio's Products & Differentiators

    CRISPR QC

    "CRISPR QC is the first CRISPR Analytics Platform. By simulating the gene editing process before introduction to cells we enable the detection and correction of errors to power the most optimal gene editing outcomes" (from crisprqc.com)

Research containing Cardea Bio

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Cardea Bio in 1 CB Insights research brief, most recently on Feb 10, 2022.

Expert Collections containing Cardea Bio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cardea Bio is included in 6 Expert Collections, including Advanced Materials.

A

Advanced Materials

1,275 items

Startups developing new or improved materials (chemicals, alloys, etc.) that provide physical or functional advantages to basic materials.

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

D

Digital Health

13,069 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

M

Medical Devices

242 items

Medical Device New Products & Services Tech MM (August 2021)

H

Health Monitoring & Diagnostics

702 items

Companies developing technology to facilitate near-patient and point-of-care (POC) in vitro diagnostic testing. Companies tagged as #NearPatient&POCTesting

S

Semiconductors, Chips, and Advanced Electronics

6,250 items

Companies in this collection develop everything from microprocessors to flash memory, integrated circuits specifically for quantum computing and artificial intelligence to OLED for displays, massive production fabs to circuit design firms, and everything in between.

Cardea Bio Patents

Cardea Bio has filed 9 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • DNA
  • DNA sequencing
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/24/2021

12/27/2022

Transistor types, Analytical chemistry, Electrodes, Electrochemistry, FETs

Grant

Application Date

5/24/2021

Grant Date

12/27/2022

Title

Related Topics

Transistor types, Analytical chemistry, Electrodes, Electrochemistry, FETs

Status

Grant

Latest Cardea Bio News

09:36 ET Previously unachievable drug discovery insights created by Cardea's BPU platform

Jan 10, 2023

News provided by Share this article Share this article SAN DIEGO, Jan. 10, 2023 /PRNewswire/ -- Today, Cardea Bio, Inc. reaches an 8-year milestone of the first external partner starting to use the BPU (Biosignal Processing Unit) platform for advancing drug discovery research to produce new and highly sought-after insights. Principal Investigator at Bar-Ilan University , Dr. Nir Qvit, shares, "It's kind of a love story between Cardea and my research, as I have already published five papers using the BPU platform. In my estimation, the BPU platform is a very important tool for drug discovery, because it's fast, easy to use, and doesn't require a lot of reagents. For example, the JoVE paper we published in March of 2022 compared a BPU assay with Isothermal Titration Calorimetry (ITC), a common biophysical measurement system. It took one day to gather the data with the BPU versus fourteen days to take the data for ITC with significantly more protein required. This exemplifies how the BPU should be an important part of the toolbox in drug discovery and a technology that all pharma companies can benefit from." While working as a postdoc at Stanford University in the Mochly-Rosen Lab , Dr. Nir Qvit's work caught the attention of Cardea's Chief Technological Officer, Brett Goldsmith, PhD, who initiated a collaboration. The partnership has continued after the Bar-Ilan University offered Dr. Qvit his own lab, focusing on chemistry and biology of protein-protein interactions for drug discovery in pharmacology. "When I learned that Dr. Qvit required in vitro proof that his peptides were binding to specific proteins, I immediately thought that this was something that we should be able to solve with our graphene Field Effect Transistor - the BPU. After attending a conference in San Francisco in January of 2015, I swung by the lab in the afternoon, before having to catch a return flight to San Diego three hours later. Nir and I tried out his biochemistry, honestly expecting that we'd just show some promise and work through refining the measurements over the next few weeks. Amazed by the great results from these very first experiments, I kept rescheduling my flight so we could run more measurements. And in the end, we captured all the measurements that closed the gap on what Nir was missing for his publication that afternoon! So even though I got home almost a day later than planned, it was a breakthrough for us and absolutely worth it," says Dr. Brett Goldsmith, CTO at Cardea Bio. "My eureka moment came after Dr. Goldsmith visited our lab and we had success on the very first day of experimenting. By the end, we had achieved the exact high value results that I could not achieve with any other technology." states Dr. Qvit, and continues, "Initially we were using the BPU platform to see binding interactions between known proteins and peptides that we designed and synthesized. Today we're also doing competitive studies to see if our peptides can inhibit protein-protein interactions. I can't wait to continue to evolve the system to accomplish cell-based assays. With Cardea, I believe the possibilities to solve some of the largest problems in drug discovery are achievable. "When I got my own lab at Bar-Ilan University in 2017, I immediately got the single-BPU Agile R100 device which just recently was upgraded to the new Gateway Reader that runs experiments on eight different BPUs at the same time. I've been impressed with how responsive Cardea has been to our needs, and in turn how they have continuously improved their platform with a rapidly expanding suite of capabilities - improved software interfaces, automated analysis, and the high quality and consistency of the BPU performance." concludes Dr. Nir Qvit of the Bar-Ilan University. Examples of Nit Qvit publications highlighting Cardea's BPU platform About the Nir Qvit Lab at Bar-Ilan Protein-protein interactions represent a significant proportion of functionally relevant biological interactions, and therefore, manipulating these interactions is an important therapeutic strategy. The main focus of the Qvit lab is the identification of molecular modulators of protein-protein interaction using bioinformatics analysis, peptide and protein chemistry, as well as system-wide biological assays. The lab goal is the development of compounds capable of modulating protein complexes that will allow a better understanding of the role of specific protein-protein interactions in cells and will be a starting point for the development of therapeutic compounds. Learn more at https://medicine.biu.ac.il/en/QvitNir ­ About Cardea Bio Cardea Bio is the world's only mass producer of a biocompatible semiconductor, the BPU ™ (Biosignal Processing Unit) Platform. The BPU is the first and only graphene semiconductor capable of translating real-time streams of biology's multiomics signals into digital information. Through the BPU™ platform, Cardea's long-term vision is to democratize access to the biosignals and insights behind the most advanced technology on our planet: Nature and biology. The Internet of Biology is that way becoming possible. Cardea's rapidly expanding IP portfolio now has 33 broad patents issued and another 34 patents pending, cementing Cardea's market-leader position in the graphene biosensor industry, where they are bringing the BPU™ (Biosignal Processing Unit) Platform to market. Cardea is headquartered in San Diego and has additional activity in Los Angeles. Cardea is a 100% American developed and built biocompatible semiconductor graphene biosensor platform for applications across a variety of sectors including human health, agriculture, molecular diagnostics, biotechnology, environmental monitoring, and animal health. Contact Cardea US phone: +1 858 319 7135 EU phone: +45 2758 2601

Cardea Bio Frequently Asked Questions (FAQ)

  • When was Cardea Bio founded?

    Cardea Bio was founded in 2013.

  • Where is Cardea Bio's headquarters?

    Cardea Bio's headquarters is located at 8969 Kenamar Dr., Suite 104, San Diego.

  • What is Cardea Bio's latest funding round?

    Cardea Bio's latest funding round is Grant.

  • How much did Cardea Bio raise?

    Cardea Bio raised a total of $22.9M.

  • Who are the investors of Cardea Bio?

    Investors of Cardea Bio include Bill & Melinda Gates Foundation, 3E Bioventures, Serra Ventures, Photon Fund, Skylight Investment and 8 more.

  • Who are Cardea Bio's competitors?

    Competitors of Cardea Bio include Ellume, Visby Medical, Baebies, MeMed, Accellix, Inflammatix, Oxford Nanopore Technologies, LumiraDx, Cue Health, Lumos Diagnostics and 22 more.

  • What products does Cardea Bio offer?

    Cardea Bio's products include CRISPR QC.

Compare Cardea Bio to Competitors

Inflammatix Logo
Inflammatix

Inflammatix is a molecular diagnostics company that develops rapid tests that read the immune system to resolve major clinical and public health challenges. The company's initial focus is on acute bacterial, viral infections, and sepsis.

Torus Biosystems Logo
Torus Biosystems

Torus Biosystems develops a syndromic diagnostic device designed for use in testing DNA for scientific and medical research purposes. Its Torus Synestia System provides seamless, comprehensive, sample-to-insight test results for major infectious diseases in a faster format than conventional methods, helping for better patient care and improved outcomes. The company was founded in 2019 and is based in Cambridge, Massachusetts.

S
Sight Diagnostics

Sight Diagnostics provides affordable and accurate diagnostics in a compact platform designed for use in qualified labs in low volume settings. Its proprietary machine-vision based technology provides the capability to perform multiple tests on a single, easy-to-operate platform.

Weavr Health Logo
Weavr Health

Weavr Health is dedicated to connecting people to health by simplifying sample collection and processing for healthcare. The Velvet device is designed so anyone, anywhere can easily collect high-quality samples without a phlebotomist. The Velvet device offers a smooth experience of blood self-collection for patients. It leverages a similar experience to traditional glucose testing, which >25% of people have experienced. Each device arrives with all that is needed to collect, package and ship quality samples to the lab for a convenient experience.

Binx Health Logo
Binx Health

Binx Health is an in vitro diagnostics Point-of-Care (POC) company that provides at-home STI testing. The platform also includes evidence-based testing, counseling, treatment, and follow up in order to increase screening and reduce infections.

Baebies Logo
Baebies

Baebies developed a nimble bioassay automation platform to rapidly perform multiplex enzymatic assays and other tests. The company licensed its core technology, digital microfluidics, from Illumina. In addition to a technology license in newborn screening that does not include sequencing, Baebies also received equipment, contracts, and other consideration in exchange for a share of ownership in the new company. The company was founded in 2013 and is based in Durham, North Carolina.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.